nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—Myelosuppression—Mitomycin—stomach cancer	0.0093	0.0596	CcSEcCtD
Ruxolitinib—BMPR2—blood vessel—stomach cancer	0.00409	0.0141	CbGeAlD
Ruxolitinib—PLK1—hematopoietic system—stomach cancer	0.00406	0.0141	CbGeAlD
Ruxolitinib—PRKG2—smooth muscle tissue—stomach cancer	0.00399	0.0138	CbGeAlD
Ruxolitinib—Myelosuppression—Fluorouracil—stomach cancer	0.00387	0.0248	CcSEcCtD
Ruxolitinib—DCLK3—hematopoietic system—stomach cancer	0.00385	0.0133	CbGeAlD
Ruxolitinib—Pancytopenia—Floxuridine—stomach cancer	0.00331	0.0212	CcSEcCtD
Ruxolitinib—CAMK1—hematopoietic system—stomach cancer	0.00317	0.011	CbGeAlD
Ruxolitinib—PRKG2—digestive system—stomach cancer	0.00315	0.0109	CbGeAlD
Ruxolitinib—MARK2—hematopoietic system—stomach cancer	0.00308	0.0107	CbGeAlD
Ruxolitinib—JAK2—blood vessel—stomach cancer	0.00294	0.0102	CbGeAlD
Ruxolitinib—Epistaxis—Floxuridine—stomach cancer	0.00293	0.0188	CcSEcCtD
Ruxolitinib—PLK1—lymphoid tissue—stomach cancer	0.00286	0.0099	CbGeAlD
Ruxolitinib—PLK1—digestive system—stomach cancer	0.00283	0.00977	CbGeAlD
Ruxolitinib—Haemoglobin—Floxuridine—stomach cancer	0.00281	0.018	CcSEcCtD
Ruxolitinib—Myelosuppression—Docetaxel—stomach cancer	0.00279	0.0179	CcSEcCtD
Ruxolitinib—Haemorrhage—Floxuridine—stomach cancer	0.00279	0.0179	CcSEcCtD
Ruxolitinib—PLK3—pancreas—stomach cancer	0.00276	0.00955	CbGeAlD
Ruxolitinib—JAK3—hematopoietic system—stomach cancer	0.00262	0.00906	CbGeAlD
Ruxolitinib—PRKG2—endocrine gland—stomach cancer	0.0026	0.00901	CbGeAlD
Ruxolitinib—JAK1—hematopoietic system—stomach cancer	0.0026	0.009	CbGeAlD
Ruxolitinib—Pancytopenia—Mitomycin—stomach cancer	0.0026	0.0167	CcSEcCtD
Ruxolitinib—PLK4—hematopoietic system—stomach cancer	0.00259	0.00895	CbGeAlD
Ruxolitinib—STK16—hematopoietic system—stomach cancer	0.00244	0.00845	CbGeAlD
Ruxolitinib—PRKCE—endocrine gland—stomach cancer	0.00243	0.00841	CbGeAlD
Ruxolitinib—HIPK2—hematopoietic system—stomach cancer	0.00243	0.0084	CbGeAlD
Ruxolitinib—JAK1—epithelium—stomach cancer	0.00238	0.00823	CbGeAlD
Ruxolitinib—Night sweats—Capecitabine—stomach cancer	0.00235	0.0151	CcSEcCtD
Ruxolitinib—PRKG2—liver—stomach cancer	0.00235	0.00812	CbGeAlD
Ruxolitinib—PLK1—endocrine gland—stomach cancer	0.00234	0.00808	CbGeAlD
Ruxolitinib—RPS6KA6—endocrine gland—stomach cancer	0.00234	0.00808	CbGeAlD
Ruxolitinib—JAK1—smooth muscle tissue—stomach cancer	0.00229	0.00793	CbGeAlD
Ruxolitinib—Anaemia—Floxuridine—stomach cancer	0.00225	0.0144	CcSEcCtD
Ruxolitinib—ROCK1—hematopoietic system—stomach cancer	0.00224	0.00775	CbGeAlD
Ruxolitinib—PRKCE—liver—stomach cancer	0.00219	0.00758	CbGeAlD
Ruxolitinib—DYRK1A—hematopoietic system—stomach cancer	0.00219	0.00756	CbGeAlD
Ruxolitinib—BMPR2—hematopoietic system—stomach cancer	0.00218	0.00753	CbGeAlD
Ruxolitinib—MARK2—digestive system—stomach cancer	0.00214	0.00741	CbGeAlD
Ruxolitinib—JAK1—pancreas—stomach cancer	0.00212	0.00733	CbGeAlD
Ruxolitinib—PLK1—liver—stomach cancer	0.00211	0.00728	CbGeAlD
Ruxolitinib—RPS6KA6—liver—stomach cancer	0.00211	0.00728	CbGeAlD
Ruxolitinib—CAMK1D—pancreas—stomach cancer	0.00207	0.00715	CbGeAlD
Ruxolitinib—DAPK3—smooth muscle tissue—stomach cancer	0.00206	0.00711	CbGeAlD
Ruxolitinib—ROCK1—epithelium—stomach cancer	0.00205	0.00709	CbGeAlD
Ruxolitinib—HIPK2—pancreas—stomach cancer	0.00198	0.00684	CbGeAlD
Ruxolitinib—ROCK1—smooth muscle tissue—stomach cancer	0.00197	0.00683	CbGeAlD
Ruxolitinib—Infection—Floxuridine—stomach cancer	0.00197	0.0126	CcSEcCtD
Ruxolitinib—PLK3—endocrine gland—stomach cancer	0.00195	0.00674	CbGeAlD
Ruxolitinib—Nervous system disorder—Floxuridine—stomach cancer	0.00195	0.0125	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Floxuridine—stomach cancer	0.00194	0.0124	CcSEcCtD
Ruxolitinib—LRRK2—hematopoietic system—stomach cancer	0.00193	0.00668	CbGeAlD
Ruxolitinib—BMPR2—smooth muscle tissue—stomach cancer	0.00192	0.00663	CbGeAlD
Ruxolitinib—DAPK3—pancreas—stomach cancer	0.0019	0.00657	CbGeAlD
Ruxolitinib—Myelosuppression—Epirubicin—stomach cancer	0.00188	0.0121	CcSEcCtD
Ruxolitinib—JAK3—lymphoid tissue—stomach cancer	0.00184	0.00638	CbGeAlD
Ruxolitinib—JAK1—lymphoid tissue—stomach cancer	0.00183	0.00634	CbGeAlD
Ruxolitinib—CAMK1—endocrine gland—stomach cancer	0.00182	0.00631	CbGeAlD
Ruxolitinib—JAK3—digestive system—stomach cancer	0.00182	0.0063	CbGeAlD
Ruxolitinib—PLK4—lymphoid tissue—stomach cancer	0.00182	0.0063	CbGeAlD
Ruxolitinib—DCLK1—digestive system—stomach cancer	0.00181	0.00626	CbGeAlD
Ruxolitinib—JAK1—digestive system—stomach cancer	0.00181	0.00626	CbGeAlD
Ruxolitinib—DYRK1A—Topotecan—Irinotecan—stomach cancer	0.00179	0.153	CbGdCrCtD
Ruxolitinib—MARK2—endocrine gland—stomach cancer	0.00177	0.00612	CbGeAlD
Ruxolitinib—MAP3K2—hematopoietic system—stomach cancer	0.00177	0.00612	CbGeAlD
Ruxolitinib—Anaemia—Mitomycin—stomach cancer	0.00176	0.0113	CcSEcCtD
Ruxolitinib—PLK3—liver—stomach cancer	0.00176	0.00608	CbGeAlD
Ruxolitinib—Myelosuppression—Doxorubicin—stomach cancer	0.00174	0.0112	CcSEcCtD
Ruxolitinib—TYK2—hematopoietic system—stomach cancer	0.00172	0.00595	CbGeAlD
Ruxolitinib—STK16—lymphoid tissue—stomach cancer	0.00172	0.00595	CbGeAlD
Ruxolitinib—HIPK2—lymphoid tissue—stomach cancer	0.00171	0.00592	CbGeAlD
Ruxolitinib—STK16—digestive system—stomach cancer	0.0017	0.00587	CbGeAlD
Ruxolitinib—MKNK2—hematopoietic system—stomach cancer	0.0017	0.00587	CbGeAlD
Ruxolitinib—IRAK1—hematopoietic system—stomach cancer	0.0017	0.00587	CbGeAlD
Ruxolitinib—NUAK2—pancreas—stomach cancer	0.00169	0.00586	CbGeAlD
Ruxolitinib—HIPK2—digestive system—stomach cancer	0.00169	0.00584	CbGeAlD
Ruxolitinib—Herpes zoster—Capecitabine—stomach cancer	0.00168	0.0108	CcSEcCtD
Ruxolitinib—PRKCE—lymph node—stomach cancer	0.00168	0.00581	CbGeAlD
Ruxolitinib—JAK1—bone marrow—stomach cancer	0.00167	0.00577	CbGeAlD
Ruxolitinib—PLK4—bone marrow—stomach cancer	0.00166	0.00573	CbGeAlD
Ruxolitinib—RET—hematopoietic system—stomach cancer	0.00166	0.00573	CbGeAlD
Ruxolitinib—CAMK1—liver—stomach cancer	0.00164	0.00569	CbGeAlD
Ruxolitinib—PLK1—Trifluridine—Floxuridine—stomach cancer	0.00164	0.14	CbGdCrCtD
Ruxolitinib—CLK2—lymphoid tissue—stomach cancer	0.00163	0.00563	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—stomach cancer	0.00161	0.00558	CbGeAlD
Ruxolitinib—PLK1—lymph node—stomach cancer	0.00161	0.00558	CbGeAlD
Ruxolitinib—DAPK2—bone marrow—stomach cancer	0.00159	0.0055	CbGeAlD
Ruxolitinib—CAMK2G—pancreas—stomach cancer	0.00159	0.00549	CbGeAlD
Ruxolitinib—ROCK1—lymphoid tissue—stomach cancer	0.00158	0.00546	CbGeAlD
Ruxolitinib—Body temperature increased—Floxuridine—stomach cancer	0.00157	0.0101	CcSEcCtD
Ruxolitinib—JAK2—hematopoietic system—stomach cancer	0.00157	0.00541	CbGeAlD
Ruxolitinib—ROCK1—digestive system—stomach cancer	0.00156	0.00539	CbGeAlD
Ruxolitinib—MKNK2—epithelium—stomach cancer	0.00155	0.00537	CbGeAlD
Ruxolitinib—MAP3K7—smooth muscle tissue—stomach cancer	0.00154	0.00534	CbGeAlD
Ruxolitinib—DYRK1A—lymphoid tissue—stomach cancer	0.00154	0.00532	CbGeAlD
Ruxolitinib—BMPR2—lymphoid tissue—stomach cancer	0.00153	0.0053	CbGeAlD
Ruxolitinib—Thrombocytopenia—Mitomycin—stomach cancer	0.00152	0.00977	CcSEcCtD
Ruxolitinib—TYK2—smooth muscle tissue—stomach cancer	0.00152	0.00524	CbGeAlD
Ruxolitinib—RET—epithelium—stomach cancer	0.00151	0.00524	CbGeAlD
Ruxolitinib—BMPR2—digestive system—stomach cancer	0.00151	0.00524	CbGeAlD
Ruxolitinib—MAP3K3—hematopoietic system—stomach cancer	0.00151	0.00522	CbGeAlD
Ruxolitinib—JAK3—endocrine gland—stomach cancer	0.00151	0.0052	CbGeAlD
Ruxolitinib—MKNK2—smooth muscle tissue—stomach cancer	0.0015	0.00517	CbGeAlD
Ruxolitinib—IRAK1—smooth muscle tissue—stomach cancer	0.0015	0.00517	CbGeAlD
Ruxolitinib—JAK1—endocrine gland—stomach cancer	0.0015	0.00517	CbGeAlD
Ruxolitinib—DCLK1—endocrine gland—stomach cancer	0.0015	0.00517	CbGeAlD
Ruxolitinib—PLK4—endocrine gland—stomach cancer	0.00149	0.00514	CbGeAlD
Ruxolitinib—CLK2—bone marrow—stomach cancer	0.00148	0.00513	CbGeAlD
Ruxolitinib—TAOK2—liver—stomach cancer	0.00148	0.00511	CbGeAlD
Ruxolitinib—CAMK1D—endocrine gland—stomach cancer	0.00146	0.00505	CbGeAlD
Ruxolitinib—Contusion—Capecitabine—stomach cancer	0.00145	0.00932	CcSEcCtD
Ruxolitinib—PHKG2—endocrine gland—stomach cancer	0.00145	0.00502	CbGeAlD
Ruxolitinib—JAK2—epithelium—stomach cancer	0.00143	0.00495	CbGeAlD
Ruxolitinib—Asthenia—Floxuridine—stomach cancer	0.00142	0.00912	CcSEcCtD
Ruxolitinib—STK16—endocrine gland—stomach cancer	0.0014	0.00485	CbGeAlD
Ruxolitinib—TYK2—pancreas—stomach cancer	0.0014	0.00485	CbGeAlD
Ruxolitinib—HIPK2—endocrine gland—stomach cancer	0.0014	0.00483	CbGeAlD
Ruxolitinib—IRAK1—pancreas—stomach cancer	0.00138	0.00478	CbGeAlD
Ruxolitinib—MKNK2—pancreas—stomach cancer	0.00138	0.00478	CbGeAlD
Ruxolitinib—JAK2—smooth muscle tissue—stomach cancer	0.00138	0.00477	CbGeAlD
Ruxolitinib—TAOK3—hematopoietic system—stomach cancer	0.00138	0.00476	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Irinotecan—stomach cancer	0.00138	0.00882	CcSEcCtD
Ruxolitinib—Bone pain—Docetaxel—stomach cancer	0.00137	0.00876	CcSEcCtD
Ruxolitinib—CAMK2G—digestive system—stomach cancer	0.00135	0.00469	CbGeAlD
Ruxolitinib—JAK1—liver—stomach cancer	0.00135	0.00466	CbGeAlD
Ruxolitinib—PLK3—lymph node—stomach cancer	0.00135	0.00466	CbGeAlD
Ruxolitinib—Fatigue—Mitomycin—stomach cancer	0.00134	0.0086	CcSEcCtD
Ruxolitinib—DAPK3—endocrine gland—stomach cancer	0.00134	0.00464	CbGeAlD
Ruxolitinib—NUAK2—bone marrow—stomach cancer	0.00133	0.00461	CbGeAlD
Ruxolitinib—CLK2—endocrine gland—stomach cancer	0.00133	0.0046	CbGeAlD
Ruxolitinib—Bone pain—Capecitabine—stomach cancer	0.00132	0.00849	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Fluorouracil—stomach cancer	0.00132	0.00844	CcSEcCtD
Ruxolitinib—CAMK1D—liver—stomach cancer	0.00132	0.00455	CbGeAlD
Ruxolitinib—PHKG2—liver—stomach cancer	0.00131	0.00452	CbGeAlD
Ruxolitinib—LTK—lymph node—stomach cancer	0.0013	0.0045	CbGeAlD
Ruxolitinib—ROCK1—endocrine gland—stomach cancer	0.00129	0.00445	CbGeAlD
Ruxolitinib—STK16—liver—stomach cancer	0.00127	0.00438	CbGeAlD
Ruxolitinib—CAMK1—lymph node—stomach cancer	0.00126	0.00436	CbGeAlD
Ruxolitinib—HIPK2—liver—stomach cancer	0.00126	0.00435	CbGeAlD
Ruxolitinib—DYRK1A—endocrine gland—stomach cancer	0.00126	0.00434	CbGeAlD
Ruxolitinib—Herpes zoster—Methotrexate—stomach cancer	0.00125	0.00804	CcSEcCtD
Ruxolitinib—BMPR2—endocrine gland—stomach cancer	0.00125	0.00433	CbGeAlD
Ruxolitinib—CAMK2G—bone marrow—stomach cancer	0.00125	0.00432	CbGeAlD
Ruxolitinib—BMP2K—bone marrow—stomach cancer	0.00125	0.00432	CbGeAlD
Ruxolitinib—MAP3K2—lymphoid tissue—stomach cancer	0.00125	0.00431	CbGeAlD
Ruxolitinib—Headache—Floxuridine—stomach cancer	0.00124	0.00797	CcSEcCtD
Ruxolitinib—LRRK2—bone marrow—stomach cancer	0.00124	0.00428	CbGeAlD
Ruxolitinib—Body temperature increased—Mitomycin—stomach cancer	0.00123	0.00789	CcSEcCtD
Ruxolitinib—PLK1—Topotecan—Irinotecan—stomach cancer	0.00123	0.104	CbGdCrCtD
Ruxolitinib—PLK4—Topotecan—Irinotecan—stomach cancer	0.00123	0.104	CbGdCrCtD
Ruxolitinib—MARK2—lymph node—stomach cancer	0.00122	0.00423	CbGeAlD
Ruxolitinib—TYK2—lymphoid tissue—stomach cancer	0.00121	0.00419	CbGeAlD
Ruxolitinib—DAPK3—liver—stomach cancer	0.00121	0.00418	CbGeAlD
Ruxolitinib—CLK2—liver—stomach cancer	0.0012	0.00414	CbGeAlD
Ruxolitinib—TYK2—digestive system—stomach cancer	0.0012	0.00414	CbGeAlD
Ruxolitinib—MKNK2—lymphoid tissue—stomach cancer	0.0012	0.00414	CbGeAlD
Ruxolitinib—MKNK2—digestive system—stomach cancer	0.00118	0.00409	CbGeAlD
Ruxolitinib—Herpes zoster—Epirubicin—stomach cancer	0.00117	0.00752	CcSEcCtD
Ruxolitinib—RET—lymphoid tissue—stomach cancer	0.00117	0.00403	CbGeAlD
Ruxolitinib—ROCK1—liver—stomach cancer	0.00116	0.00402	CbGeAlD
Ruxolitinib—RET—digestive system—stomach cancer	0.00115	0.00398	CbGeAlD
Ruxolitinib—MAP3K2—bone marrow—stomach cancer	0.00113	0.00392	CbGeAlD
Ruxolitinib—DYRK1A—liver—stomach cancer	0.00113	0.00392	CbGeAlD
Ruxolitinib—TAOK2—lymph node—stomach cancer	0.00113	0.00392	CbGeAlD
Ruxolitinib—BMPR2—liver—stomach cancer	0.00113	0.0039	CbGeAlD
Ruxolitinib—MAP3K7—bone marrow—stomach cancer	0.00112	0.00389	CbGeAlD
Ruxolitinib—TAOK3—pancreas—stomach cancer	0.00112	0.00387	CbGeAlD
Ruxolitinib—CAMK2G—endocrine gland—stomach cancer	0.00112	0.00387	CbGeAlD
Ruxolitinib—BMP2K—endocrine gland—stomach cancer	0.00112	0.00387	CbGeAlD
Ruxolitinib—Asthenia—Mitomycin—stomach cancer	0.00112	0.00716	CcSEcCtD
Ruxolitinib—Neutropenia—Irinotecan—stomach cancer	0.00111	0.00713	CcSEcCtD
Ruxolitinib—LRRK2—endocrine gland—stomach cancer	0.00111	0.00384	CbGeAlD
Ruxolitinib—TYK2—bone marrow—stomach cancer	0.0011	0.00382	CbGeAlD
Ruxolitinib—JAK2—lymphoid tissue—stomach cancer	0.0011	0.00381	CbGeAlD
Ruxolitinib—IRAK1—bone marrow—stomach cancer	0.00109	0.00377	CbGeAlD
Ruxolitinib—MKNK2—bone marrow—stomach cancer	0.00109	0.00377	CbGeAlD
Ruxolitinib—JAK2—digestive system—stomach cancer	0.00109	0.00377	CbGeAlD
Ruxolitinib—Herpes zoster—Doxorubicin—stomach cancer	0.00109	0.00696	CcSEcCtD
Ruxolitinib—Pancytopenia—Fluorouracil—stomach cancer	0.00108	0.00693	CcSEcCtD
Ruxolitinib—NUAK2—liver—stomach cancer	0.00108	0.00373	CbGeAlD
Ruxolitinib—Weight decreased—Irinotecan—stomach cancer	0.00108	0.00689	CcSEcCtD
Ruxolitinib—JAK3—lymph node—stomach cancer	0.00104	0.0036	CbGeAlD
Ruxolitinib—JAK1—lymph node—stomach cancer	0.00103	0.00358	CbGeAlD
Ruxolitinib—DCLK1—lymph node—stomach cancer	0.00103	0.00358	CbGeAlD
Ruxolitinib—Dizziness—Mitomycin—stomach cancer	0.00103	0.0066	CcSEcCtD
Ruxolitinib—PLK4—lymph node—stomach cancer	0.00103	0.00355	CbGeAlD
Ruxolitinib—MAP3K2—endocrine gland—stomach cancer	0.00102	0.00352	CbGeAlD
Ruxolitinib—Infestation—Fluorouracil—stomach cancer	0.00101	0.00651	CcSEcCtD
Ruxolitinib—Infestation NOS—Fluorouracil—stomach cancer	0.00101	0.00651	CcSEcCtD
Ruxolitinib—CAMK2G—liver—stomach cancer	0.00101	0.00349	CbGeAlD
Ruxolitinib—BMP2K—liver—stomach cancer	0.00101	0.00349	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—stomach cancer	0.00101	0.00349	CbGeAlD
Ruxolitinib—JAK2—bone marrow—stomach cancer	0.001	0.00347	CbGeAlD
Ruxolitinib—PHKG2—lymph node—stomach cancer	0.001	0.00347	CbGeAlD
Ruxolitinib—LRRK2—liver—stomach cancer	0.001	0.00346	CbGeAlD
Ruxolitinib—TYK2—endocrine gland—stomach cancer	0.000989	0.00342	CbGeAlD
Ruxolitinib—Urinary tract infection—Fluorouracil—stomach cancer	0.000987	0.00633	CcSEcCtD
Ruxolitinib—DAPK2—lymph node—stomach cancer	0.000986	0.00341	CbGeAlD
Ruxolitinib—MKNK2—endocrine gland—stomach cancer	0.000976	0.00338	CbGeAlD
Ruxolitinib—Headache—Mitomycin—stomach cancer	0.000975	0.00625	CcSEcCtD
Ruxolitinib—STK16—lymph node—stomach cancer	0.00097	0.00336	CbGeAlD
Ruxolitinib—TAOK3—lymphoid tissue—stomach cancer	0.000969	0.00335	CbGeAlD
Ruxolitinib—MAP3K3—bone marrow—stomach cancer	0.000967	0.00335	CbGeAlD
Ruxolitinib—HIPK2—lymph node—stomach cancer	0.000965	0.00334	CbGeAlD
Ruxolitinib—Epistaxis—Fluorouracil—stomach cancer	0.000957	0.00614	CcSEcCtD
Ruxolitinib—TAOK3—digestive system—stomach cancer	0.000957	0.00331	CbGeAlD
Ruxolitinib—Haemoglobin—Irinotecan—stomach cancer	0.000956	0.00613	CcSEcCtD
Ruxolitinib—RET—endocrine gland—stomach cancer	0.000952	0.00329	CbGeAlD
Ruxolitinib—Haemorrhage—Irinotecan—stomach cancer	0.000951	0.0061	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Docetaxel—stomach cancer	0.000951	0.00609	CcSEcCtD
Ruxolitinib—DAPK3—lymph node—stomach cancer	0.000927	0.00321	CbGeAlD
Ruxolitinib—Bone pain—Epirubicin—stomach cancer	0.000922	0.00591	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Capecitabine—stomach cancer	0.00092	0.0059	CcSEcCtD
Ruxolitinib—CLK2—lymph node—stomach cancer	0.000919	0.00318	CbGeAlD
Ruxolitinib—MAP3K2—liver—stomach cancer	0.000917	0.00317	CbGeAlD
Ruxolitinib—Haemoglobin—Fluorouracil—stomach cancer	0.000916	0.00587	CcSEcCtD
Ruxolitinib—Haemorrhage—Fluorouracil—stomach cancer	0.000911	0.00584	CcSEcCtD
Ruxolitinib—MAP3K7—liver—stomach cancer	0.000908	0.00314	CbGeAlD
Ruxolitinib—JAK2—endocrine gland—stomach cancer	0.0009	0.00311	CbGeAlD
Ruxolitinib—TYK2—liver—stomach cancer	0.000892	0.00308	CbGeAlD
Ruxolitinib—TAOK3—bone marrow—stomach cancer	0.000882	0.00305	CbGeAlD
Ruxolitinib—IRAK1—liver—stomach cancer	0.00088	0.00304	CbGeAlD
Ruxolitinib—MKNK2—liver—stomach cancer	0.00088	0.00304	CbGeAlD
Ruxolitinib—DYRK1A—lymph node—stomach cancer	0.000868	0.003	CbGeAlD
Ruxolitinib—MAP3K3—endocrine gland—stomach cancer	0.000867	0.003	CbGeAlD
Ruxolitinib—BMPR2—lymph node—stomach cancer	0.000865	0.00299	CbGeAlD
Ruxolitinib—Bone pain—Doxorubicin—stomach cancer	0.000853	0.00547	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Docetaxel—stomach cancer	0.000838	0.00538	CcSEcCtD
Ruxolitinib—NUAK2—lymph node—stomach cancer	0.000827	0.00286	CbGeAlD
Ruxolitinib—Flatulence—Irinotecan—stomach cancer	0.000816	0.00523	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Capecitabine—stomach cancer	0.000812	0.0052	CcSEcCtD
Ruxolitinib—JAK2—liver—stomach cancer	0.000811	0.00281	CbGeAlD
Ruxolitinib—TAOK3—endocrine gland—stomach cancer	0.000791	0.00273	CbGeAlD
Ruxolitinib—MAP3K3—liver—stomach cancer	0.000782	0.0027	CbGeAlD
Ruxolitinib—Pancytopenia—Docetaxel—stomach cancer	0.00078	0.005	CcSEcCtD
Ruxolitinib—BMP2K—lymph node—stomach cancer	0.000774	0.00268	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—stomach cancer	0.000774	0.00268	CbGeAlD
Ruxolitinib—Neutropenia—Docetaxel—stomach cancer	0.000768	0.00493	CcSEcCtD
Ruxolitinib—LRRK2—lymph node—stomach cancer	0.000767	0.00265	CbGeAlD
Ruxolitinib—Anaemia—Irinotecan—stomach cancer	0.000765	0.00491	CcSEcCtD
Ruxolitinib—Pancytopenia—Capecitabine—stomach cancer	0.000755	0.00484	CcSEcCtD
Ruxolitinib—Weight increased—Docetaxel—stomach cancer	0.000748	0.00479	CcSEcCtD
Ruxolitinib—Neutropenia—Capecitabine—stomach cancer	0.000744	0.00477	CcSEcCtD
Ruxolitinib—Weight decreased—Docetaxel—stomach cancer	0.000743	0.00477	CcSEcCtD
Ruxolitinib—Anaemia—Fluorouracil—stomach cancer	0.000733	0.0047	CcSEcCtD
Ruxolitinib—Infestation NOS—Docetaxel—stomach cancer	0.000733	0.0047	CcSEcCtD
Ruxolitinib—Infestation—Docetaxel—stomach cancer	0.000733	0.0047	CcSEcCtD
Ruxolitinib—Weight increased—Capecitabine—stomach cancer	0.000724	0.00464	CcSEcCtD
Ruxolitinib—Weight decreased—Capecitabine—stomach cancer	0.00072	0.00461	CcSEcCtD
Ruxolitinib—TAOK3—liver—stomach cancer	0.000713	0.00247	CbGeAlD
Ruxolitinib—Infestation NOS—Capecitabine—stomach cancer	0.000709	0.00455	CcSEcCtD
Ruxolitinib—Infestation—Capecitabine—stomach cancer	0.000709	0.00455	CcSEcCtD
Ruxolitinib—MAP3K2—lymph node—stomach cancer	0.000703	0.00243	CbGeAlD
Ruxolitinib—MAP3K7—lymph node—stomach cancer	0.000696	0.00241	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Docetaxel—stomach cancer	0.000693	0.00444	CcSEcCtD
Ruxolitinib—Epistaxis—Docetaxel—stomach cancer	0.000691	0.00443	CcSEcCtD
Ruxolitinib—Urinary tract infection—Capecitabine—stomach cancer	0.000689	0.00442	CcSEcCtD
Ruxolitinib—TYK2—lymph node—stomach cancer	0.000684	0.00236	CbGeAlD
Ruxolitinib—Haematuria—Capecitabine—stomach cancer	0.000676	0.00434	CcSEcCtD
Ruxolitinib—MKNK2—lymph node—stomach cancer	0.000675	0.00233	CbGeAlD
Ruxolitinib—IRAK1—lymph node—stomach cancer	0.000675	0.00233	CbGeAlD
Ruxolitinib—Infection—Irinotecan—stomach cancer	0.000671	0.0043	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Capecitabine—stomach cancer	0.000671	0.0043	CcSEcCtD
Ruxolitinib—Epistaxis—Capecitabine—stomach cancer	0.000669	0.00429	CcSEcCtD
Ruxolitinib—Nervous system disorder—Irinotecan—stomach cancer	0.000663	0.00425	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Irinotecan—stomach cancer	0.000662	0.00424	CcSEcCtD
Ruxolitinib—Haemoglobin—Docetaxel—stomach cancer	0.000661	0.00424	CcSEcCtD
Ruxolitinib—RET—lymph node—stomach cancer	0.000658	0.00228	CbGeAlD
Ruxolitinib—Haemorrhage—Docetaxel—stomach cancer	0.000658	0.00422	CcSEcCtD
Ruxolitinib—Infection—Fluorouracil—stomach cancer	0.000643	0.00412	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Epirubicin—stomach cancer	0.000641	0.00411	CcSEcCtD
Ruxolitinib—Haemoglobin—Capecitabine—stomach cancer	0.00064	0.0041	CcSEcCtD
Ruxolitinib—PLK1—Cladribine—Floxuridine—stomach cancer	0.000639	0.0545	CbGdCrCtD
Ruxolitinib—Haemorrhage—Capecitabine—stomach cancer	0.000637	0.00408	CcSEcCtD
Ruxolitinib—Nervous system disorder—Fluorouracil—stomach cancer	0.000635	0.00407	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Fluorouracil—stomach cancer	0.000634	0.00406	CcSEcCtD
Ruxolitinib—JAK2—lymph node—stomach cancer	0.000622	0.00215	CbGeAlD
Ruxolitinib—MAP3K3—lymph node—stomach cancer	0.000599	0.00207	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—stomach cancer	0.000593	0.0038	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Irinotecan—stomach cancer	0.000584	0.00374	CcSEcCtD
Ruxolitinib—Fatigue—Irinotecan—stomach cancer	0.000583	0.00374	CcSEcCtD
Ruxolitinib—Malnutrition—Docetaxel—stomach cancer	0.000572	0.00367	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Epirubicin—stomach cancer	0.000566	0.00363	CcSEcCtD
Ruxolitinib—Pancytopenia—Methotrexate—stomach cancer	0.000562	0.00361	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Fluorouracil—stomach cancer	0.000559	0.00358	CcSEcCtD
Ruxolitinib—Malnutrition—Capecitabine—stomach cancer	0.000554	0.00355	CcSEcCtD
Ruxolitinib—Neutropenia—Methotrexate—stomach cancer	0.000554	0.00355	CcSEcCtD
Ruxolitinib—TAOK3—lymph node—stomach cancer	0.000547	0.00189	CbGeAlD
Ruxolitinib—Flatulence—Capecitabine—stomach cancer	0.000546	0.0035	CcSEcCtD
Ruxolitinib—Body temperature increased—Irinotecan—stomach cancer	0.000534	0.00343	CcSEcCtD
Ruxolitinib—Anaemia—Docetaxel—stomach cancer	0.000529	0.00339	CcSEcCtD
Ruxolitinib—Infestation NOS—Methotrexate—stomach cancer	0.000528	0.00339	CcSEcCtD
Ruxolitinib—Infestation—Methotrexate—stomach cancer	0.000528	0.00339	CcSEcCtD
Ruxolitinib—Pancytopenia—Epirubicin—stomach cancer	0.000526	0.00337	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—stomach cancer	0.000523	0.00335	CcSEcCtD
Ruxolitinib—Neutropenia—Epirubicin—stomach cancer	0.000518	0.00332	CcSEcCtD
Ruxolitinib—Anaemia—Capecitabine—stomach cancer	0.000512	0.00328	CcSEcCtD
Ruxolitinib—Body temperature increased—Fluorouracil—stomach cancer	0.000512	0.00328	CcSEcCtD
Ruxolitinib—Weight increased—Epirubicin—stomach cancer	0.000504	0.00323	CcSEcCtD
Ruxolitinib—Haematuria—Methotrexate—stomach cancer	0.000503	0.00323	CcSEcCtD
Ruxolitinib—Weight decreased—Epirubicin—stomach cancer	0.000501	0.00321	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Methotrexate—stomach cancer	0.000499	0.0032	CcSEcCtD
Ruxolitinib—Epistaxis—Methotrexate—stomach cancer	0.000498	0.00319	CcSEcCtD
Ruxolitinib—Infestation—Epirubicin—stomach cancer	0.000494	0.00317	CcSEcCtD
Ruxolitinib—Infestation NOS—Epirubicin—stomach cancer	0.000494	0.00317	CcSEcCtD
Ruxolitinib—Pancytopenia—Doxorubicin—stomach cancer	0.000487	0.00312	CcSEcCtD
Ruxolitinib—Asthenia—Irinotecan—stomach cancer	0.000485	0.00311	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—stomach cancer	0.000484	0.0031	CcSEcCtD
Ruxolitinib—Urinary tract infection—Epirubicin—stomach cancer	0.00048	0.00308	CcSEcCtD
Ruxolitinib—Neutropenia—Doxorubicin—stomach cancer	0.000479	0.00307	CcSEcCtD
Ruxolitinib—Haemoglobin—Methotrexate—stomach cancer	0.000476	0.00305	CcSEcCtD
Ruxolitinib—Haemorrhage—Methotrexate—stomach cancer	0.000474	0.00304	CcSEcCtD
Ruxolitinib—Haematuria—Epirubicin—stomach cancer	0.000471	0.00302	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	0.000469	0.003	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Epirubicin—stomach cancer	0.000467	0.003	CcSEcCtD
Ruxolitinib—Weight increased—Doxorubicin—stomach cancer	0.000467	0.00299	CcSEcCtD
Ruxolitinib—Epistaxis—Epirubicin—stomach cancer	0.000466	0.00299	CcSEcCtD
Ruxolitinib—Infection—Docetaxel—stomach cancer	0.000464	0.00298	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—stomach cancer	0.000464	0.00297	CcSEcCtD
Ruxolitinib—Nervous system disorder—Docetaxel—stomach cancer	0.000458	0.00294	CcSEcCtD
Ruxolitinib—Pruritus—Fluorouracil—stomach cancer	0.000458	0.00294	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Docetaxel—stomach cancer	0.000457	0.00293	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—stomach cancer	0.000457	0.00293	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—stomach cancer	0.000457	0.00293	CcSEcCtD
Ruxolitinib—Skin disorder—Docetaxel—stomach cancer	0.000454	0.00291	CcSEcCtD
Ruxolitinib—Infection—Capecitabine—stomach cancer	0.000449	0.00288	CcSEcCtD
Ruxolitinib—Dizziness—Irinotecan—stomach cancer	0.000447	0.00287	CcSEcCtD
Ruxolitinib—Haemoglobin—Epirubicin—stomach cancer	0.000446	0.00286	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—stomach cancer	0.000444	0.00285	CcSEcCtD
Ruxolitinib—Nervous system disorder—Capecitabine—stomach cancer	0.000444	0.00284	CcSEcCtD
Ruxolitinib—Haemorrhage—Epirubicin—stomach cancer	0.000444	0.00284	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Capecitabine—stomach cancer	0.000443	0.00284	CcSEcCtD
Ruxolitinib—Skin disorder—Capecitabine—stomach cancer	0.000439	0.00282	CcSEcCtD
Ruxolitinib—Haematuria—Doxorubicin—stomach cancer	0.000436	0.00279	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—stomach cancer	0.000432	0.00277	CcSEcCtD
Ruxolitinib—Epistaxis—Doxorubicin—stomach cancer	0.000431	0.00276	CcSEcCtD
Ruxolitinib—Dizziness—Fluorouracil—stomach cancer	0.000428	0.00274	CcSEcCtD
Ruxolitinib—Headache—Irinotecan—stomach cancer	0.000423	0.00271	CcSEcCtD
Ruxolitinib—DYRK1A—Doxorubicin—Epirubicin—stomach cancer	0.000422	0.0359	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Epirubicin—stomach cancer	0.000422	0.0359	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Epirubicin—stomach cancer	0.000422	0.0359	CbGdCrCtD
Ruxolitinib—CYP3A4—hematopoietic system—stomach cancer	0.000418	0.00145	CbGeAlD
Ruxolitinib—Malnutrition—Methotrexate—stomach cancer	0.000413	0.00265	CcSEcCtD
Ruxolitinib—Haemoglobin—Doxorubicin—stomach cancer	0.000413	0.00264	CcSEcCtD
Ruxolitinib—Haemorrhage—Doxorubicin—stomach cancer	0.00041	0.00263	CcSEcCtD
Ruxolitinib—Headache—Fluorouracil—stomach cancer	0.000406	0.0026	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Docetaxel—stomach cancer	0.000403	0.00259	CcSEcCtD
Ruxolitinib—Fatigue—Docetaxel—stomach cancer	0.000403	0.00258	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Capecitabine—stomach cancer	0.000391	0.0025	CcSEcCtD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—stomach cancer	0.00039	0.0332	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—stomach cancer	0.00039	0.0332	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—stomach cancer	0.00039	0.0332	CbGdCrCtD
Ruxolitinib—Fatigue—Capecitabine—stomach cancer	0.00039	0.0025	CcSEcCtD
Ruxolitinib—Malnutrition—Epirubicin—stomach cancer	0.000386	0.00248	CcSEcCtD
Ruxolitinib—Anaemia—Methotrexate—stomach cancer	0.000381	0.00244	CcSEcCtD
Ruxolitinib—Flatulence—Epirubicin—stomach cancer	0.00038	0.00244	CcSEcCtD
Ruxolitinib—Body temperature increased—Docetaxel—stomach cancer	0.000369	0.00237	CcSEcCtD
Ruxolitinib—Body temperature increased—Capecitabine—stomach cancer	0.000358	0.00229	CcSEcCtD
Ruxolitinib—Malnutrition—Doxorubicin—stomach cancer	0.000357	0.00229	CcSEcCtD
Ruxolitinib—Anaemia—Epirubicin—stomach cancer	0.000357	0.00229	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—stomach cancer	0.000352	0.00226	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	0.000349	0.00224	CcSEcCtD
Ruxolitinib—Asthenia—Docetaxel—stomach cancer	0.000335	0.00215	CcSEcCtD
Ruxolitinib—Infection—Methotrexate—stomach cancer	0.000335	0.00214	CcSEcCtD
Ruxolitinib—Pruritus—Docetaxel—stomach cancer	0.000331	0.00212	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methotrexate—stomach cancer	0.00033	0.00212	CcSEcCtD
Ruxolitinib—Anaemia—Doxorubicin—stomach cancer	0.00033	0.00212	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Methotrexate—stomach cancer	0.00033	0.00211	CcSEcCtD
Ruxolitinib—Skin disorder—Methotrexate—stomach cancer	0.000327	0.0021	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	0.000326	0.00209	CcSEcCtD
Ruxolitinib—Asthenia—Capecitabine—stomach cancer	0.000325	0.00208	CcSEcCtD
Ruxolitinib—Pruritus—Capecitabine—stomach cancer	0.00032	0.00205	CcSEcCtD
Ruxolitinib—Infection—Epirubicin—stomach cancer	0.000313	0.00201	CcSEcCtD
Ruxolitinib—Nervous system disorder—Epirubicin—stomach cancer	0.000309	0.00198	CcSEcCtD
Ruxolitinib—Dizziness—Docetaxel—stomach cancer	0.000309	0.00198	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Epirubicin—stomach cancer	0.000309	0.00198	CcSEcCtD
Ruxolitinib—Skin disorder—Epirubicin—stomach cancer	0.000306	0.00196	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	0.000302	0.00194	CcSEcCtD
Ruxolitinib—Dizziness—Capecitabine—stomach cancer	0.000299	0.00192	CcSEcCtD
Ruxolitinib—Headache—Docetaxel—stomach cancer	0.000293	0.00188	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Methotrexate—stomach cancer	0.000291	0.00186	CcSEcCtD
Ruxolitinib—CYP3A4—digestive system—stomach cancer	0.000291	0.00101	CbGeAlD
Ruxolitinib—Fatigue—Methotrexate—stomach cancer	0.00029	0.00186	CcSEcCtD
Ruxolitinib—Infection—Doxorubicin—stomach cancer	0.00029	0.00186	CcSEcCtD
Ruxolitinib—PLK1—Idarubicin—Epirubicin—stomach cancer	0.000288	0.0245	CbGdCrCtD
Ruxolitinib—PLK4—Doxorubicin—Epirubicin—stomach cancer	0.000288	0.0245	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Epirubicin—stomach cancer	0.000288	0.0245	CbGdCrCtD
Ruxolitinib—PLK1—Doxorubicin—Epirubicin—stomach cancer	0.000288	0.0245	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Epirubicin—stomach cancer	0.000288	0.0245	CbGdCrCtD
Ruxolitinib—Nervous system disorder—Doxorubicin—stomach cancer	0.000286	0.00183	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Doxorubicin—stomach cancer	0.000286	0.00183	CcSEcCtD
Ruxolitinib—Headache—Capecitabine—stomach cancer	0.000283	0.00182	CcSEcCtD
Ruxolitinib—Skin disorder—Doxorubicin—stomach cancer	0.000283	0.00182	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Epirubicin—stomach cancer	0.000272	0.00174	CcSEcCtD
Ruxolitinib—Fatigue—Epirubicin—stomach cancer	0.000272	0.00174	CcSEcCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—stomach cancer	0.000266	0.0227	CbGdCrCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—stomach cancer	0.000266	0.0227	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—stomach cancer	0.000266	0.0227	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—stomach cancer	0.000266	0.0227	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—stomach cancer	0.000266	0.0227	CbGdCrCtD
Ruxolitinib—Body temperature increased—Methotrexate—stomach cancer	0.000266	0.00171	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.000252	0.00161	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—stomach cancer	0.000251	0.00161	CcSEcCtD
Ruxolitinib—Body temperature increased—Epirubicin—stomach cancer	0.000249	0.0016	CcSEcCtD
Ruxolitinib—Asthenia—Methotrexate—stomach cancer	0.000242	0.00155	CcSEcCtD
Ruxolitinib—CYP3A4—endocrine gland—stomach cancer	0.00024	0.000831	CbGeAlD
Ruxolitinib—Pruritus—Methotrexate—stomach cancer	0.000238	0.00153	CcSEcCtD
Ruxolitinib—Body temperature increased—Doxorubicin—stomach cancer	0.000231	0.00148	CcSEcCtD
Ruxolitinib—Asthenia—Epirubicin—stomach cancer	0.000226	0.00145	CcSEcCtD
Ruxolitinib—Pruritus—Epirubicin—stomach cancer	0.000223	0.00143	CcSEcCtD
Ruxolitinib—Dizziness—Methotrexate—stomach cancer	0.000223	0.00143	CcSEcCtD
Ruxolitinib—CYP3A4—liver—stomach cancer	0.000217	0.000749	CbGeAlD
Ruxolitinib—Headache—Methotrexate—stomach cancer	0.000211	0.00135	CcSEcCtD
Ruxolitinib—Asthenia—Doxorubicin—stomach cancer	0.000209	0.00134	CcSEcCtD
Ruxolitinib—Dizziness—Epirubicin—stomach cancer	0.000208	0.00134	CcSEcCtD
Ruxolitinib—Pruritus—Doxorubicin—stomach cancer	0.000206	0.00132	CcSEcCtD
Ruxolitinib—Headache—Epirubicin—stomach cancer	0.000197	0.00127	CcSEcCtD
Ruxolitinib—Dizziness—Doxorubicin—stomach cancer	0.000193	0.00124	CcSEcCtD
Ruxolitinib—Headache—Doxorubicin—stomach cancer	0.000183	0.00117	CcSEcCtD
Ruxolitinib—TYK2—Immune System—STAT3—stomach cancer	4.24e-06	7.8e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCND1—stomach cancer	4.23e-06	7.79e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—JUN—stomach cancer	4.22e-06	7.77e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—MAPK1—stomach cancer	4.22e-06	7.76e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—stomach cancer	4.22e-06	7.76e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ERBB2—stomach cancer	4.21e-06	7.75e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—RHOA—stomach cancer	4.2e-06	7.73e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HRAS—stomach cancer	4.19e-06	7.71e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PIK3CA—stomach cancer	4.18e-06	7.7e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—stomach cancer	4.17e-06	7.69e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MAPK3—stomach cancer	4.17e-06	7.68e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6R—stomach cancer	4.17e-06	7.67e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CDKN1A—stomach cancer	4.16e-06	7.66e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOS3—stomach cancer	4.16e-06	7.65e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SERPINE1—stomach cancer	4.14e-06	7.63e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MAPK3—stomach cancer	4.12e-06	7.59e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—STAT3—stomach cancer	4.11e-06	7.57e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—stomach cancer	4.11e-06	7.56e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CDKN1A—stomach cancer	4.09e-06	7.53e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—UMPS—stomach cancer	4.09e-06	7.53e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK8—stomach cancer	4.06e-06	7.48e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MAPK3—stomach cancer	4.05e-06	7.46e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PIK3CA—stomach cancer	4.03e-06	7.43e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HRAS—stomach cancer	4.02e-06	7.41e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SERPINE1—stomach cancer	4.02e-06	7.41e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—stomach cancer	4.01e-06	7.38e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MYC—stomach cancer	4.01e-06	7.38e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—RHOA—stomach cancer	4e-06	7.36e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK8—stomach cancer	3.99e-06	7.35e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—KRAS—stomach cancer	3.98e-06	7.33e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IRS2—stomach cancer	3.97e-06	7.31e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MAPK1—stomach cancer	3.97e-06	7.31e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—stomach cancer	3.97e-06	7.31e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NOS3—stomach cancer	3.96e-06	7.29e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAPK3—stomach cancer	3.93e-06	7.23e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MAPK1—stomach cancer	3.92e-06	7.22e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—stomach cancer	3.92e-06	7.22e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—STAT3—stomach cancer	3.91e-06	7.2e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SERPINE1—stomach cancer	3.9e-06	7.19e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—stomach cancer	3.9e-06	7.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDKN1B—stomach cancer	3.9e-06	7.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ERBB2—stomach cancer	3.89e-06	7.16e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RHOA—stomach cancer	3.88e-06	7.15e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—stomach cancer	3.87e-06	7.12e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MAPK1—stomach cancer	3.85e-06	7.09e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—stomach cancer	3.85e-06	7.09e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—stomach cancer	3.85e-06	7.09e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CAV1—stomach cancer	3.85e-06	7.09e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOA1—stomach cancer	3.84e-06	7.07e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NOS3—stomach cancer	3.84e-06	7.07e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1B—stomach cancer	3.83e-06	7.05e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—stomach cancer	3.8e-06	7e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PDHA1—stomach cancer	3.8e-06	7e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ECHS1—stomach cancer	3.8e-06	7e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RHOA—stomach cancer	3.76e-06	6.93e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—stomach cancer	3.75e-06	6.9e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—stomach cancer	3.75e-06	6.9e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MAPK3—stomach cancer	3.74e-06	6.88e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAPK1—stomach cancer	3.74e-06	6.88e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—stomach cancer	3.74e-06	6.88e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—stomach cancer	3.73e-06	6.87e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOS3—stomach cancer	3.73e-06	6.86e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—JUN—stomach cancer	3.71e-06	6.84e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—STAT3—stomach cancer	3.71e-06	6.83e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—stomach cancer	3.7e-06	6.82e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—stomach cancer	3.7e-06	6.82e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB2—stomach cancer	3.7e-06	6.81e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—stomach cancer	3.69e-06	6.79e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PRKCB—stomach cancer	3.66e-06	6.75e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—stomach cancer	3.66e-06	6.74e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—stomach cancer	3.65e-06	6.72e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6ST—stomach cancer	3.65e-06	6.72e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—stomach cancer	3.64e-06	6.7e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—stomach cancer	3.64e-06	6.69e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1B—stomach cancer	3.6e-06	6.63e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDKN1A—stomach cancer	3.6e-06	6.63e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB2—stomach cancer	3.59e-06	6.62e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TYMP—stomach cancer	3.57e-06	6.58e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—FADS1—stomach cancer	3.57e-06	6.58e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—stomach cancer	3.57e-06	6.58e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MAPK1—stomach cancer	3.56e-06	6.55e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—stomach cancer	3.56e-06	6.55e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK3—stomach cancer	3.55e-06	6.53e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—stomach cancer	3.53e-06	6.5e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK8—stomach cancer	3.51e-06	6.47e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL8—stomach cancer	3.51e-06	6.46e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APC—stomach cancer	3.51e-06	6.46e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK3—stomach cancer	3.49e-06	6.42e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB2—stomach cancer	3.48e-06	6.42e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—stomach cancer	3.45e-06	6.35e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—stomach cancer	3.44e-06	6.34e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1B—stomach cancer	3.43e-06	6.31e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL8—stomach cancer	3.41e-06	6.27e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—stomach cancer	3.4e-06	6.27e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—stomach cancer	3.39e-06	6.25e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—stomach cancer	3.39e-06	6.23e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK1—stomach cancer	3.37e-06	6.21e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—stomach cancer	3.37e-06	6.21e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—stomach cancer	3.36e-06	6.19e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK3—stomach cancer	3.36e-06	6.18e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SREBF2—stomach cancer	3.35e-06	6.16e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—stomach cancer	3.34e-06	6.16e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1B—stomach cancer	3.33e-06	6.13e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1A—stomach cancer	3.32e-06	6.12e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK1—stomach cancer	3.32e-06	6.11e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—stomach cancer	3.32e-06	6.11e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—RORA—stomach cancer	3.31e-06	6.09e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL8—stomach cancer	3.3e-06	6.08e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—stomach cancer	3.29e-06	6.06e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—stomach cancer	3.27e-06	6.02e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—JUN—stomach cancer	3.26e-06	6.01e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6R—stomach cancer	3.26e-06	6e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—stomach cancer	3.24e-06	5.97e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—stomach cancer	3.24e-06	5.97e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1B—stomach cancer	3.23e-06	5.94e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—stomach cancer	3.21e-06	5.91e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK1—stomach cancer	3.2e-06	5.88e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—stomach cancer	3.2e-06	5.88e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—stomach cancer	3.19e-06	5.87e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—stomach cancer	3.19e-06	5.87e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—stomach cancer	3.17e-06	5.85e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—stomach cancer	3.17e-06	5.84e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—JUN—stomach cancer	3.17e-06	5.83e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1A—stomach cancer	3.16e-06	5.82e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—stomach cancer	3.15e-06	5.8e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—stomach cancer	3.13e-06	5.77e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALDOB—stomach cancer	3.1e-06	5.71e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—stomach cancer	3.09e-06	5.69e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK8—stomach cancer	3.09e-06	5.68e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—stomach cancer	3.09e-06	5.68e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—stomach cancer	3.08e-06	5.67e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—stomach cancer	3.08e-06	5.67e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—JUN—stomach cancer	3.07e-06	5.66e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1A—stomach cancer	3.07e-06	5.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK3—stomach cancer	3.07e-06	5.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—stomach cancer	3.05e-06	5.62e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—stomach cancer	3.05e-06	5.61e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SERPINE1—stomach cancer	3.05e-06	5.61e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—stomach cancer	3.02e-06	5.56e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—stomach cancer	3.01e-06	5.55e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—stomach cancer	3e-06	5.52e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK8—stomach cancer	3e-06	5.52e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—stomach cancer	2.99e-06	5.5e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1A—stomach cancer	2.98e-06	5.48e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—stomach cancer	2.97e-06	5.46e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—stomach cancer	2.96e-06	5.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RHOA—stomach cancer	2.94e-06	5.42e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—stomach cancer	2.93e-06	5.39e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK1—stomach cancer	2.92e-06	5.38e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—stomach cancer	2.92e-06	5.37e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOS3—stomach cancer	2.91e-06	5.36e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK8—stomach cancer	2.91e-06	5.35e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALOX5—stomach cancer	2.88e-06	5.3e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—stomach cancer	2.88e-06	5.3e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—stomach cancer	2.87e-06	5.29e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—stomach cancer	2.86e-06	5.26e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—stomach cancer	2.85e-06	5.25e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—DPYD—stomach cancer	2.83e-06	5.22e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK3—stomach cancer	2.83e-06	5.22e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—stomach cancer	2.83e-06	5.22e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—stomach cancer	2.82e-06	5.2e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—stomach cancer	2.79e-06	5.13e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—stomach cancer	2.77e-06	5.11e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—stomach cancer	2.77e-06	5.1e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—stomach cancer	2.76e-06	5.08e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—stomach cancer	2.76e-06	5.07e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—stomach cancer	2.74e-06	5.05e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—stomach cancer	2.73e-06	5.03e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB2—stomach cancer	2.72e-06	5.01e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—stomach cancer	2.71e-06	4.99e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK3—stomach cancer	2.7e-06	4.97e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK1—stomach cancer	2.7e-06	4.96e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—stomach cancer	2.7e-06	4.96e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—stomach cancer	2.68e-06	4.94e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—stomach cancer	2.66e-06	4.91e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—stomach cancer	2.66e-06	4.89e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—stomach cancer	2.62e-06	4.83e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK3—stomach cancer	2.62e-06	4.82e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—stomach cancer	2.59e-06	4.77e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL8—stomach cancer	2.58e-06	4.75e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK1—stomach cancer	2.57e-06	4.72e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—stomach cancer	2.57e-06	4.72e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—stomach cancer	2.57e-06	4.72e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—stomach cancer	2.55e-06	4.7e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—stomach cancer	2.55e-06	4.69e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—stomach cancer	2.55e-06	4.69e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK3—stomach cancer	2.54e-06	4.68e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—stomach cancer	2.53e-06	4.66e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1B—stomach cancer	2.52e-06	4.64e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTT1—stomach cancer	2.51e-06	4.61e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK1—stomach cancer	2.49e-06	4.59e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—stomach cancer	2.49e-06	4.59e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2A6—stomach cancer	2.48e-06	4.56e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—stomach cancer	2.47e-06	4.55e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—stomach cancer	2.46e-06	4.52e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—stomach cancer	2.42e-06	4.46e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK1—stomach cancer	2.42e-06	4.45e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—stomach cancer	2.42e-06	4.45e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKR1C3—stomach cancer	2.41e-06	4.44e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—stomach cancer	2.41e-06	4.43e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—JUN—stomach cancer	2.4e-06	4.42e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—stomach cancer	2.35e-06	4.33e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ENO1—stomach cancer	2.35e-06	4.32e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—stomach cancer	2.34e-06	4.32e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—stomach cancer	2.34e-06	4.31e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—stomach cancer	2.34e-06	4.3e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1A—stomach cancer	2.33e-06	4.29e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—stomach cancer	2.28e-06	4.2e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK8—stomach cancer	2.27e-06	4.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—stomach cancer	2.24e-06	4.13e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—stomach cancer	2.23e-06	4.1e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—stomach cancer	2.16e-06	3.98e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—stomach cancer	2.16e-06	3.98e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—stomach cancer	2.15e-06	3.97e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—stomach cancer	2.1e-06	3.86e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—stomach cancer	2.1e-06	3.86e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—stomach cancer	2.09e-06	3.85e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CD44—stomach cancer	2.08e-06	3.83e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—stomach cancer	2.08e-06	3.82e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—stomach cancer	2.07e-06	3.81e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—stomach cancer	2.06e-06	3.79e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—stomach cancer	2.03e-06	3.73e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—stomach cancer	2e-06	3.68e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK3—stomach cancer	1.98e-06	3.65e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—stomach cancer	1.97e-06	3.63e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—stomach cancer	1.94e-06	3.57e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—stomach cancer	1.93e-06	3.55e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—stomach cancer	1.91e-06	3.52e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK1—stomach cancer	1.89e-06	3.48e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—stomach cancer	1.89e-06	3.48e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—stomach cancer	1.86e-06	3.42e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—stomach cancer	1.78e-06	3.28e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPP2R1A—stomach cancer	1.77e-06	3.26e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTP1—stomach cancer	1.74e-06	3.2e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HMOX1—stomach cancer	1.71e-06	3.15e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—stomach cancer	1.64e-06	3.02e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TYMS—stomach cancer	1.61e-06	2.97e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTM1—stomach cancer	1.6e-06	2.94e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—stomach cancer	1.58e-06	2.92e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—stomach cancer	1.52e-06	2.79e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ERCC2—stomach cancer	1.5e-06	2.76e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—stomach cancer	1.45e-06	2.67e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTHFR—stomach cancer	1.41e-06	2.6e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CAV1—stomach cancer	1.3e-06	2.4e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOA1—stomach cancer	1.3e-06	2.39e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARG—stomach cancer	1.14e-06	2.11e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALB—stomach cancer	1.03e-06	1.89e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NOS3—stomach cancer	9.84e-07	1.81e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—stomach cancer	9e-07	1.66e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—stomach cancer	5.54e-07	1.02e-06	CbGpPWpGaD
